Roivant CEO Matt Gline at #BIO24 (Brian Benton Photography)
September 18, 2024 10:57 AM EDT
Deals

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

Max Bayer

Pharma Reporter

Roivant is once again reap­ing the ben­e­fits of its be­spoke busi­ness mod­el. This time, it’s sell­ing Der­ma­vant to Organon for up to $1.2 bil­lion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times